Ascendis Pharma A/s
Could not find a ticker for this position, may be a filing error
A Danish biopharmaceutical company that builds long-acting versions of existing medicines using its TransCon (transient conjugation) platform, which links a drug to a carrier molecule so it releases slowly in the body. Its approved products include Skytrofa for growth hormone deficiency and Yorvipath for hypoparathyroidism. Founded in Copenhagen in 2007 by entrepreneur Jan Møller Mikkelsen, the company takes its name from the Latin "ascendere," meaning "to climb."
2.25% Convertible Senior Notes due 2028
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Artisan Partners Asset Management Inc. | 13G/APassive | 4.2% | 2.63M | Aug 13, 2026 |
| Artisan Partners Holdings LP | 13G/APassive | 4.2% | 2.63M | Aug 13, 2026 |
| Artisan Investments GP LLC | 13G/APassive | 4.2% | 2.63M | Aug 13, 2026 |
| Artisan Partners Limited Partnership | 13G/APassive | 4.2% | 2.63M | Aug 13, 2026 |
| JANUS HENDERSON GROUP PLC | 13G/APassive | 6% | 3.72M | May 15, 2026 |
| Capital International Investors | 13G/APassive | 3.2% | 2.01M | May 14, 2026 |
| T. Rowe Price Investment Management, Inc. | 13G/APassive | 10.5% | 6.51M | May 7, 2026 |
| FMR LLC | 13G/APassive | 6.6% | 3.85M | May 6, 2026 |
| Abigail P. Johnson | 13G/APassive | 6.6% | 3.85M | May 6, 2026 |
| Westfield Capital Management Company, L.P. | 13G/APassive | 8.48% | 5.19M | Feb 11, 2026 |